title: Bipolar depression: Managing patients with second generation antipsychotics.
abstract: Bipolar affective disorder is a debilitating illness that manifests as cyclical episodes of mood elevation and depression, but the treatment of the depressive episodes (i.e., bipolar depression) differs considerably from the treatment of major depressive disorder. In bipolar affective disorder, it is well known that patients spend a significantly greater amount of time in depressive episodes than manic or hypomanic episodes, yet there are currently just three Food and Drug Administration-approved agents for the treatment of bipolar depression: (1) olanzapine/fluoxetine combination (2) quetiapine, both immediate- and extended-release, and (3) lurasidone. The literature review presented here focuses on the clinical trials that led to the Food and Drug Administration-approval of these second generation antipsychotics in the treatment of bipolar depression. The discussion highlights key considerations regarding overall treatment strategies to aid clinicians in the selection of pharmacologic agents. Recommended monitoring parameters, potential adverse effects, and pertinent counseling points for second generation antipsychotics used in bipolar depression are included.
authors.affiliation: South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC, USA.
authors.forename: Lindsay M
authors.initials: LM
authors.lastname: Avery
authors.affiliation: South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC, USA draytons@musc.edu.
authors.forename: Shannon J
authors.initials: SJ
authors.lastname: Drayton
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D006801:Humans
chemical_list: D014150:Antipsychotic Agents
keywords: bipolar disorder depression; lurasidone; olanzapine/fluoxetine; quetiapine; second generation antipsychotics